10 studies found for:
J591
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Unknown † |
Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer
|
||||
| 2 | Unknown † |
Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody
|
||||
| 3 | Recruiting |
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
|
||||
| 4 | Unknown † |
Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer
|
||||
| 5 | Unknown † |
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
|
||||
| 6 | Completed |
Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2
|
||||
| 7 | Completed |
Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate
|
||||
| 8 | Completed |
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
|
||||
| 9 | Completed |
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
|
||||
| 10 | Recruiting |
Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer
|
† Indicates status has not been verified in more than two years